ATE197478T1 - Auswirkungen von aktinfilamenten auf die struktur und lyse von fribringerinnseln - Google Patents

Auswirkungen von aktinfilamenten auf die struktur und lyse von fribringerinnseln

Info

Publication number
ATE197478T1
ATE197478T1 AT93919997T AT93919997T ATE197478T1 AT E197478 T1 ATE197478 T1 AT E197478T1 AT 93919997 T AT93919997 T AT 93919997T AT 93919997 T AT93919997 T AT 93919997T AT E197478 T1 ATE197478 T1 AT E197478T1
Authority
AT
Austria
Prior art keywords
clots
actin
fribrary
lysis
effects
Prior art date
Application number
AT93919997T
Other languages
English (en)
Inventor
Paul A Janmey
Jennifer A Lamb
Stuart E Lind
Thomas P Stossel
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE197478T1 publication Critical patent/ATE197478T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT93919997T 1992-08-14 1993-08-13 Auswirkungen von aktinfilamenten auf die struktur und lyse von fribringerinnseln ATE197478T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/929,203 US5691160A (en) 1992-08-14 1992-08-14 Effects of actin filaments of fibrin clot structure and lysis
PCT/US1993/007584 WO1994004704A1 (en) 1992-08-14 1993-08-13 Effects of actin filaments on fibrin clot structure and lysis

Publications (1)

Publication Number Publication Date
ATE197478T1 true ATE197478T1 (de) 2000-11-11

Family

ID=25457479

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93919997T ATE197478T1 (de) 1992-08-14 1993-08-13 Auswirkungen von aktinfilamenten auf die struktur und lyse von fribringerinnseln

Country Status (11)

Country Link
US (1) US5691160A (de)
EP (1) EP0655089B1 (de)
JP (1) JPH08500488A (de)
AT (1) ATE197478T1 (de)
CA (1) CA2142121C (de)
DE (1) DE69329652T2 (de)
DK (1) DK0655089T3 (de)
ES (1) ES2151517T3 (de)
GR (1) GR3034823T3 (de)
PT (1) PT655089E (de)
WO (1) WO1994004704A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
WO1998055455A2 (en) * 1997-06-05 1998-12-10 Hemosphere, Inc. Modification of platelet action by fibrinogen-coated particles
US6264988B1 (en) 1997-06-05 2001-07-24 Hemosphere, Inc. Fibrinogen-coated microspheres
FR2781055B1 (fr) * 1998-07-09 2000-10-13 Immunotech Sa Reactif et methode pour la permeabilisation et l'identification des erythrocytes
CA2380972A1 (en) * 1999-08-13 2001-02-22 Hemodyne, Inc. Method of using platelet contractile force and whole blood clot elastic modulus as clinical markers
US7301020B2 (en) * 2003-06-19 2007-11-27 Wisconsin Alumni Research Foundation Macrolide analogs and methods for identifying same
US20070238655A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
CN1980694B (zh) * 2004-05-12 2012-09-26 布赖汉姆妇女医院有限公司 凝溶胶蛋白治疗感染的用途
GB0507981D0 (en) * 2005-04-20 2005-05-25 Uws Ventures Ltd Method of determining the point at which coagulating blood forms a clot
JP2009530613A (ja) * 2006-03-15 2009-08-27 ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用
US8198094B2 (en) 2006-03-15 2012-06-12 The Brigham And Women's Hospital, Inc. Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis
EP2708603B1 (de) 2008-01-25 2017-04-19 The General Hospital Corporation Diagnostische und therapeutische Verwendungen von Gelsolin bei Nierenversagen
CA2811493C (en) * 2010-09-15 2020-06-16 Debiopharm International Sa Method for separating target molecules or particles from fibrinogen-containing samples including blood components
KR101416954B1 (ko) * 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988010259A1 (en) * 1987-06-19 1988-12-29 Syracuse University Cytochalasin purification methods and compositions
US5177002A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
US5177001A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor
US5326749A (en) * 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
ES2124702T3 (es) * 1990-04-11 1999-02-16 Brigham & Womens Hospital Usos terapeuticos de compuestos que se unen a actina.
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I

Also Published As

Publication number Publication date
WO1994004704A1 (en) 1994-03-03
JPH08500488A (ja) 1996-01-23
CA2142121C (en) 2003-09-09
EP0655089B1 (de) 2000-11-08
DK0655089T3 (da) 2001-02-12
ES2151517T3 (es) 2001-01-01
DE69329652T2 (de) 2001-06-13
CA2142121A1 (en) 1994-03-03
US5691160A (en) 1997-11-25
EP0655089A4 (de) 1997-04-02
GR3034823T3 (en) 2001-02-28
PT655089E (pt) 2001-04-30
DE69329652D1 (de) 2000-12-14
EP0655089A1 (de) 1995-05-31

Similar Documents

Publication Publication Date Title
DE69329652D1 (de) Auswirkungen von aktinfilamenten auf die struktur und lyse von fribringerinnseln
DE68929551D1 (de) Menschliche DNase
CL2009002139A1 (es) Peptido sintetico que comprende la secuencia sec id no:6 y sec id no:7 de la proteina gp41 del virus vih con actividad antiretroviral.
DE3877529D1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
ES2179077T3 (es) Acido glutamico decarboxilasa clonada.
DE60140794D1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
ATE431364T1 (de) Inhibitoren der menschlichen elastase von neutrophilen
DE3686295D1 (de) Reinigung von koagulationsfaktoren des blutes und von anderen proteinen auf sulfatierten nicht carbohydratierten matrizen.
ATE246248T1 (de) Anti-hiv-proteine gap31, dap30 und dap32, die sie kodierende dna und ihre therapeutische nutzung
FR2656214B1 (fr) Cadre dynamique d'osteosynthese du rachis.
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
NO875069D0 (no) Hybride proteiner.
AU2157888A (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
BR9007115A (pt) Novo trombolitico
DE68917353D1 (de) N-Alkoxyalkylamide von Hydroxysauren und sie enthaltende Hautbehandlungszubereitungen.
DE69013011D1 (de) Bcrf1-proteine als inhibitoren von interferon-g(g).
DE3886517D1 (de) Menschlicher Prourokinase ähnliches Polypeptid.
NO954888D0 (no) Farmasöytiske preparater og deres anvendelse, særlig for behandling av neuro-degenerative sykdommer
ATE139565T1 (de) Solubilisierung und reinigung des rezeptors für das gastrin-freisetzende peptid
NO890932D0 (no) Modifiserte proteiner.
Mizutani 6th International Congress on Placental Proteins. Basic and Clinical Aspects
NO900121L (no) Probursin.
Grining History and goals of the humanistic psychology
FR2623628B1 (fr) Serum etalon, de nature humaine, reconstitue a partir des fractions rejetees (non utilisees en therapeutique), du fractionnement du plasma humain, du sang humain, du sang placentaire ou retroplacentaire
IT1218502B (it) Fascia tensoria per l'aumento della circolazione sanguigna e della elasticita' del cuoio capelluto

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee